Understanding how SIGLEC-15 affects the immune response in tumors
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment
This study is looking at a protein called SIGLEC-15 that can keep your immune system from fighting cancer, and by blocking it, the researchers hope to boost the activity of T-cells, which are important for battling tumors, especially in cancers that don’t respond to other treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10988287 on NIH RePORTER |
What this research studies
This research investigates the role of SIGLEC-15, a protein that suppresses the immune response in the tumor microenvironment, particularly in cancers that do not express PD-L1. The team has developed a genome-scale screening method to identify how this protein interacts with T-cells, which are crucial for fighting cancer. By blocking SIGLEC-15 with a monoclonal antibody, the researchers aim to enhance T-cell activity against tumors, potentially leading to improved cancer treatments. The study focuses on understanding the unique characteristics of SIGLEC-15 compared to other immune checkpoint proteins.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer, particularly those whose tumors do not express PD-L1.
Not a fit: Patients with cancers that are already effectively treated by existing PD-1/PD-L1 therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy options for patients with cancers that are currently difficult to treat.
How similar studies have performed: Other research has shown promising results with similar immune checkpoint blockade approaches, indicating potential for success in this novel area.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Wang, Jun — New York University School of Medicine
- Study coordinator: Wang, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.